The trial included 239 adults with IDH2-mutated relapsed/refractory AML or myelodysplastic syndromes with refractory anemia with excess blasts (RAEB), with AML patients representing the largest subgroup in the study (74% of all patients; Stein et al., 2017). The gene discussed is IDH2; the disease is acute myeloid leukemia.